Nrx Pharmaceuticals Stock Performance
| NRXPW Stock | USD 0.15 0.04 21.05% |
NRx Pharmaceuticals holds a performance score of 12 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -3.02, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning NRx Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, NRx Pharmaceuticals is expected to outperform it. Use NRx Pharmaceuticals treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to analyze future returns on NRx Pharmaceuticals.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in NRx Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, NRx Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 20.1 M |
NRx |
NRx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7.10 in NRx Pharmaceuticals on November 2, 2024 and sell it today you would earn a total of 7.90 from holding NRx Pharmaceuticals or generate 111.27% return on investment over 90 days. NRx Pharmaceuticals is currently producing 3.2127% returns and takes up 20.9263% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than NRx, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NRx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NRx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NRx Pharmaceuticals, and traders can use it to determine the average amount a NRx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1535
| Best Portfolio | Best Equity | |||
| Good Returns | NRXPW | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 20.93 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.21 actual daily | 64 64% of assets have lower returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average NRx Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NRx Pharmaceuticals by adding it to a well-diversified portfolio.
NRx Pharmaceuticals Fundamentals Growth
NRx Stock prices reflect investors' perceptions of the future prospects and financial health of NRx Pharmaceuticals, and NRx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NRx Stock performance.
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| EBITDA | (30.02 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Earnings Per Share | (6.25) X | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
About NRx Pharmaceuticals Performance
Evaluating NRx Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NRx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NRx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about NRx Pharmaceuticals performance evaluation
Checking the ongoing alerts about NRx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NRx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NRx Pharmaceuticals is way too risky over 90 days horizon | |
| NRx Pharmaceuticals has some characteristics of a very speculative penny stock | |
| NRx Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| NRx Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (30.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NRx Pharmaceuticals has accumulated about 24.55 M in cash with (21.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing NRx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NRx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining NRx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NRx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NRx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NRx Pharmaceuticals' stock. These opinions can provide insight into NRx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NRx Stock Analysis
When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.